Medicare caps what seniors pay for chronic drugs—not what plans pay
S. 2770 — Share the Savings with Seniors Act · Filed by John Cornyn (R-TX) · 3 cosponsors · Introduced Sep 11, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare Part D drug plans to cap cost-sharing for chronic care drugs (like diabetes medications, blood thinners, and asthma inhalers) at the drug's net price—the actual price the plan pays after manufacturer rebates—rather than allowing plans to charge patients a percentage of a higher list price. Starting in 2027, seniors with chronic conditions would pay less out-of-pocket for these essential medications, and low-income beneficiaries would see their copayments capped at the same level as other enrollees.
Why we flagged it
The bill's core mechanism is a regulatory cap on patient cost-sharing for chronic medications under Medicare Part D, tied to net price rather than list price. This is a consumer-protection measure within the existing Medicare framework, not a tax, subsidy, or structural overhaul.
What the text implies
- Pharmaceutical manufacturers may face pressure to reduce rebates or negotiate lower net prices, since the cap eliminates the 'list price markup' that previously allowed plans to shift costs to patients while pocketing rebate savings.
- PBMs (pharmacy benefit managers) lose a revenue stream: the ability to charge patients coinsurance based on list price while retaining rebates. This may reduce their negotiating leverage or profitability on chronic-care drugs.
The full analysis lists 5 implications of this text.
Who stands to gain
Medicare beneficiaries (seniors and disabled individuals); Low-income seniors (dual-eligible and LIS recipients)